Mucosal atomization devices market to reach $1.52 billion by 2030

The mucosal atomization devices market is projected to grow from $0.92 billion in 2025 to $1.52 billion by 2030, driven by demand for non-invasive drug delivery in emergency care, outpatient settings and home healthcare. The Business Research Company says rising allergic rhinitis cases and broader use of portable, needle-free systems are helping fuel the expansion.

Why it matters: - Mucosal atomization devices are gaining traction as a needle-free way to deliver drugs through the nose and other mucosal surfaces. - The market is being shaped by higher demand in emergency care, anesthesia care, outpatient treatment and home healthcare. - Rising allergic rhinitis cases are increasing the need for fast nasal drug delivery that can reduce congestion, sneezing and inflammation.

What happened: - The Business Research Company released its Mucosal Atomization Devices Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The market is expected to rise from $0.92 billion in 2025 to $1.02 billion in 2026. - The report projects the market will reach $1.52 billion by 2030. - The report places the market in a 10.9% CAGR from 2025 to 2026 and a 10.5% CAGR through the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Mucosal atomization devices deliver medication through the nasal passages and provide atomization across the mucous membranes of the nose and oropharyngeal areas. - The devices are used to deliver atomized drugs to the nasal cavity, oral cavity, larynx, trachea and lungs. - Growth drivers include more use of nasal drug delivery techniques, more emergency medical interventions, expansion of outpatient facilities, availability of atomization-based therapies and greater clinical awareness of mucosal drug administration. - Longer-term growth factors include the preference for non-invasive drug delivery, wider use in emergency and anesthesia care, adoption in home healthcare, stronger infection-control priorities and portable medical delivery technology. - The report expects broader adoption of needle-free delivery systems, demand for fast-acting emergency medications, more single-use atomization devices, portable atomization solutions and a stronger focus on patient comfort and safety. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also includes market attractiveness scoring, total addressable market analysis, company scoring matrices, Excel dashboards, market-hotspot infographics, technology trends and updated graphics and tables. - The Business Research Company offers a free sample of the report and a full version online: Download a free sample and View the full report.

Between the lines: - The forecast points to steady demand for drug-delivery tools that avoid needles and work in urgent care settings. - The allergic rhinitis trend suggests the market is benefiting from a broader burden of nasal inflammation tied to pollution, allergens and urbanization. - UK Health Security Agency data cited in the report showed a sharp rise in allergic rhinitis consultations in January 2024 during week 23, alongside elevated grass pollen levels and warmer weather. - The highest consultation rates were recorded among people ages 5-14 and 15-44.

What's next: - The market is likely to keep expanding as healthcare systems look for faster, more comfortable and more portable delivery options. - The report points to continued growth in single-use and portable atomization devices as well as broader use in emergency settings. - Regional growth momentum is expected to shift toward Asia-Pacific even as North America remains a major market.

The bottom line: - Mucosal atomization devices are moving from a niche delivery method to a faster-growing segment of non-invasive drug administration, with the strongest demand coming from emergency care and rising nasal-allergy treatment needs.